Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Rocket Pharmaceuticals, Inc.
  6. Summary
    RCKT   US77313F1066

ROCKET PHARMACEUTICALS, INC.

(RCKT)
  Report
Delayed Nasdaq  -  04:00 2022-07-06 pm EDT
16.15 USD   +3.99%
09:07aSVB Securities Adjusts Price Target on Rocket Pharmaceuticals to $64 From $66, Keeps Outperform Rating
MT
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQGM : RCKT) dropped from Russell 3000 Growth Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQGM : RCKT) added to Russell Microcap Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
13.03(c) 13.76(c) 14.45(c) 15.53(c) 16.15 Last
560 204 714 151 1 012 023 704 943 916 581 Volume
+1.24% +5.60% +5.01% +7.47% +3.99% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 0,13 M - -
Net income 2022 -186 M - -
Net cash position 2022 239 M - -
P/E ratio 2022 -5,81x
Yield 2022 -
Sales 2023 61,4 M - -
Net income 2023 -176 M - -
Net cash position 2023 178 M - -
P/E ratio 2023 -7,77x
Yield 2023 -
Capitalization 1 063 M 1 063 M -
EV / Sales 2022 6 590x
EV / Sales 2023 14,4x
Nbr of Employees 151
Free-Float 93,1%
More Financials
Company
Rocket Pharmaceuticals, Inc. is a clinical-stage, multi-platform biotechnology company that is focused on the development of gene therapies for rare and devastating diseases. The Company’s clinical-stage ex vivo lentiviral vector (LVV) programs include Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Danon Disease, Pyruvate Kinase Deficiency (PKD) and Infantile Malignant Osteopetrosis (IMO). FA is a... 
Read more
More about the company
Ratings of Rocket Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about ROCKET PHARMACEUTICALS, INC.
09:07aSVB Securities Adjusts Price Target on Rocket Pharmaceuticals to $64 From $66, Keeps Ou..
MT
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) dropped from Russell 3000 Growth Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell Microcap Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell Microcap Value Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) dropped from Russell 2000 Growth Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) dropped from Russell 2500 Growth Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) dropped from Russell Small Cap Comp Growth In..
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell 2000 Value Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell 3000 Value Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell 3000E Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell 3000E Value Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) dropped from Russell 3000E Growth Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell 2500 Value Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell Small Cap Comp Value Index
CI
06/15ROCKET PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8..
AQ
More news
News in other languages on ROCKET PHARMACEUTICALS, INC.
05/19Rocket Pharmaceuticals présente des données de premier plan positives sur le programme ..
05/16Rocket Pharmaceuticals, Inc. présente des données cliniques positives issues des progra..
05/05Rocket Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre se termina..
04/04Rocket Pharmaceuticals nomme Fady Malik au conseil d'administration
03/11Rocket Pharmaceuticals, Inc. annonce des changements de direction
More news
Analyst Recommendations on ROCKET PHARMACEUTICALS, INC.
More recommendations
Chart ROCKET PHARMACEUTICALS, INC.
Duration : Period :
Rocket Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCKET PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 16,15 $
Average target price 57,40 $
Spread / Average Target 255%
EPS Revisions
Managers and Directors
Gaurav D. Shah Chief Executive Officer & Director
Kinnari Patel President & Chief Operating Officer
John C. Militello Treasurer, Chief Financial & Accounting Officer
Roderick T. Wong Chairman
Jonathan David Schwartz Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ROCKET PHARMACEUTICALS, INC.-26.02%1 022
GILEAD SCIENCES, INC.-14.14%78 194
VERTEX PHARMACEUTICALS31.59%73 908
REGENERON PHARMACEUTICALS, INC.-5.54%64 277
WUXI APPTEC CO., LTD.-4.67%49 127
BIONTECH SE-37.54%39 133